Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
By Antonio C. Wolff, M. Hammond, David G. Hicks, Mitchell Dowsett, Lisa M. McShane, Kimberly H. Allison, D. Allred, J. Bartlett, M. Bilous, P. Fitzgibbons and 10 more. Journal of Clinical Oncology, 2013
4,808 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/d2f21bff821802e438d3e4d2234d690b3dc4c049
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Mitchell Dowsett
- A. Stanisławek
- Marcin Czeczelewski
- Sergiusz Łukasiewicz
- Robert Sitarz
- J. Baj
- Alicja Forma
Citations in the corpus
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, methodology): “In line with the new ASCO HER2 guidelines, if an HER2 test result is ultimately deemed to be equivocal, even after reflex testing with an alternative assay, HER2-targeted therapy may also be considered [18].”
- Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications (2014, neutral): “Therefore, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have recommended guidelines in HER2 testing to ensure accuracy [57].”
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016, neutral): “HER2 testing guidelines specifically recommended that individual assays of amplification or overexpression be used.(3,16) Therefore, to the extent possible, the panel evaluated each tumor biomarker assay for a given biomarker and made recommendations for each”
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 (2016, methodology): “Antitumor activity of DS-8201a in low HER2–expressing tumors T-DM1 has been approved for HER2-positive metastatic breast cancer patients, defined as being HER2 IHC 3þ or IHC 2þ/FISH–positive according to the current guidelines (45), and there are still clinical unmet needs in FISH-negative, HER2 1þ ”